CN105944096A - Immunoenhancer for chicken vaccine - Google Patents
Immunoenhancer for chicken vaccine Download PDFInfo
- Publication number
- CN105944096A CN105944096A CN201610293284.7A CN201610293284A CN105944096A CN 105944096 A CN105944096 A CN 105944096A CN 201610293284 A CN201610293284 A CN 201610293284A CN 105944096 A CN105944096 A CN 105944096A
- Authority
- CN
- China
- Prior art keywords
- chicken
- vaccine
- immunostimulant
- recombinant
- recombination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses an immunoenhancer for a chicken vaccine; and the immunoenhancer, which is a cell factor compound of chicken genetic engineering, is prepared through compatibility and combination of a recombinant chicken interferon alpha, a recombinant chicken interferon [gamma] and a recombinant chicken IL-2. The immunoenhancer for the chicken vaccine disclosed by the invention, when used, is added to the vaccine by an addition amount of 1-30% of the vaccine; the immunoenhancer is capable of effectively improving cellular immune response and body liquid cellular immune response levels of the vaccine; and the application scope of the immunoenhancer includes chicken inactivated vaccines, genetic engineering vaccines and attenuated live vaccines.
Description
Technical field
The invention belongs to veterinary biologics technical field, relate in particular to a kind of chicken vaccine immunostimulant.
Background technology
It is most important the simplest that vaccine immunity is usually preventing and treating poultry infectious disease, is also one of maximally effective means, and immunization and follow-up ill generation can directly be affected by the effect of vaccine immunity.If some animals are after immune vaccine, it are not above immunization time section and occurred as soon as infectious disease, then this time immunity is the most unsuccessful.Having the quality problems of vaccine itself, the problem such as also have immune operation improper, immuning failure has many factors to be caused.But scientific and effective carrying out immunity, and the effect of vaccine reaches optimum state, the immunologic function strengthening vaccine is most important.
Since first nineteen twenty-five Ramon finds to add the specific immune response that certain other materials (agar, slaine, lecithin and Saponin) can improve antigen in vaccine, the most various different materials are used as immunological adjuvant or immunostimulant.Immunological adjuvant or immunostimulant refer to apply prior to antigen or with antigen simultaneously, can change or the enhancing body specific immune response to this antigen, can strengthen the immunogenicity of corresponding antigens or change immunoreation type, and the material of no antigen own.For multiple infectious disease perhaps, owing to not having suitable immunological adjuvant to have impact on the development of vaccine, poison Seedling, recombiant protein, polypeptide and DNA vaccination etc..Therefore, the prevention and control of infectious disease are in addition to the vaccine developing high-efficiency low-toxicity, and the research and development of immunological adjuvant also play vital effect.
The feature of Utopian vaccine immunopotentiator is to promote summation action original with vaccine on protective immune response；Can effectively excite stronger cellullar immunologic response, mucosa-immune etc.；Safety, toxic and side effects is little；The structure of adjuvant and composition and biological characteristics are stablized, it is easy to degradation in vivo and removing；Wide adaptability, be prone to storage.Chicken vaccine immunity adjuvant is mainly oil emulsion in the market, there is injection site abscess, tuberosity, bursts the formation die young and cause the problems such as acute or chronic inflammatory reaction, and inducing machine somatic cell immunne response effect is uncertain.
Two during the last ten years, scholars using cytokine as in terms of vaccine adjuvant, many deep explorations are made, and obtaining a lot of soul-stirring result: cytokine can increase conventional vaccine to varying degrees, immunological effect including inactivated vaccine, Attenuate vaccine, subunit vaccine, and nucleic acid vaccine: 1. can significantly strengthen the Positive seroconversion rate of vaccine；2. the NAT in body can be significantly improved；3. the generation time of antibody is shortened；4. cellullar immunologic response is strengthened.In human interferon is applied, interferon routine as rabies virus vaccine immunological adjuvant and is used widely: in rabies virus-immune answering, the most not only has humoral immunization to participate in, and has the mediated immunity response of cell to participate in.After rabies virus enters body, in addition to main infringement nervous system, lymphoid tissue is also had and significantly affects, especially T lymphocyte, and less on bone-marrow-derived lymphocyte impact.This hydrophobe the lowest with some neutralizing antibody levels fails to avoid the phenomenon of death and matches.Therefore, when promptly preventing and treating rabies, not only to consider to improve specificity neutralizing antibody level, and to manage to improve specificity cellular immunity response function.Interferon-' alpha ', during 1993 to 1996 years, has been done a large amount of clinical trial as adjuvant and rabies vaccine use in conjunction: the protective inoculation to 13000 many cases rabies vaccine adds l agent IFN-α, does not all find vaccine immunity failure case by Ministry of Public Health.Concentrating 4 mad dogs bites in event, increases by 1 dose of IFN-α, none failure case, and have 4 example morbidity death in 10 examples of conventional injectable vaccines when 33 example head pins vaccinate.From this, during people's injecting pstudorabies vaccine, first pin injection increases by 1 dose of IFN-α as adjuvant simultaneously.
In veterinary applications, cytokine the most gradually comes into one's own as the application of vaccine immunity adjuvant, and a kind of Novel chicken vaccine immunostimulant that the present invention develops, is chicken genetically engineered cell factor coniplexes.Chicken genetically engineered cell factor coniplexes formula is restructuring chicken interferon α 30% ~ 80%, recombination chicken interferon gamma 10% ~ 40%, recombinant IL-2 10% ~ 40%.Adding in vaccine uses, addition is the 1 ~ 30% of vaccine, can be effectively improved cellullar immunologic response and the humoral immunoresponse(HI) level of chicken vaccine；Range includes chicken inactivated vaccine, recombinant vaccine and attenuated live vaccine.
Summary of the invention
It is an object of the invention to provide a kind of Novel chicken vaccine immunostimulant, utilize chicken genetically engineered cell factor coniplexes to be used as vaccine immunity adjuvant, this immunostimulant is applied widely, can be effectively improved cells in vivo immunne response level.Specifically, present invention employs techniques below scheme.
A kind of chicken vaccine immunostimulant, it is characterized in that, described chicken vaccine immunostimulant is formed by proper ratio compatible combination by chicken genetically engineered cell factor coniplexes, described chicken genetically engineered cell factor coniplexes includes recombination chicken interferon-ALPHA, recombination chicken interferon gamma and recombinant IL-2, and this three kinds of chicken genetically engineered cell factors ratio by mass in the composite is restructuring chicken interferon α 30% ~ 80%, recombination chicken interferon gamma 10% ~ 40%, recombinant IL-2 10% ~ 40%.
Preferably, described chicken vaccine immunostimulant consumption in bacterin preparation, based on the total amount of three kinds of recombinant cytokines in described cytokine complex with the weight of vaccine, in cytokine complex, three kinds of recombinant cytokine gross weights are the 1 ~ 30% of vaccine weight.
In above scheme, the recombination chicken interferon-ALPHA in described chicken vaccine immunostimulant is as described in the sequence 1 in sequence table.
Further, the recombination chicken interferon gamma in described chicken vaccine immunostimulant is as described in the sequence 2 in sequence table.
It addition, the recombinant IL-2 in described chicken vaccine immunostimulant is as described in the sequence 3 in sequence table.
Further, described chicken vaccine immunostimulant is to be prepared as water soluble preparation.
Preferably, described chicken vaccine immunostimulant is the lyophilized preparation that can restore with water, in described lyophilized preparation in addition to three kinds of recombinant cytokines, also comprises appropriate freeze drying protectant, and described freeze drying protectant comprises defatted milk powder, glucose and serum albumin.
It is an object of the invention to provide a kind of Novel chicken vaccine immunostimulant, be chicken genetically engineered cell factor coniplexes, formula is restructuring chicken interferon α 30% ~ 80%, recombination chicken interferon gamma 10% ~ 40%, recombinant IL-2 10% ~ 40%.The positive effect of the present invention is:
1. can improve the humoral immunoresponse(HI) level of chicken vaccine: this immunostimulant adds in chicken vaccine uses; addition is the 1 ~ 30% of vaccine; immunity chicken wing venous blood collection detection finds that vaccine protection period neutralizing antibody level can improve 2 ~ 4 times; neutralizing antibody produces window phase and shortens 30 ~ 50%, and humoral immunoresponse(HI) mark IL-4 secretory volume is relatively used alone vaccine and can improve 1 ~ 3 times.
2. can improve the cellullar immunologic response level of chicken vaccine: this immunostimulant adds in chicken vaccine uses, and addition is the 1 ~ 30% of vaccine, cellullar immunologic response mark CD3+Number and CD4+/CD8+T percentage of lymphocyte is relatively used alone vaccine and improves.
3. safety is good, can be prepared as water solublity, solves chicken vaccine immunity adjuvant in the market and there is injection site abscess, tuberosity, bursts the formation die young and cause the problems such as acute or chronic inflammatory reaction.
4. noresidue in body, this immunostimulant is recombinant cytokine protein, also contains in normal chicken body, uses and has no side effect without any residual.
Accompanying drawing explanation
Fig. 1 Novel chicken vaccine immunostimulant improves ND Vaccine immunity chicken neutralizing antibody level；
Fig. 2 Novel chicken vaccine immunostimulant improves ND Vaccine immunity chicken IL-4 secretion level.
Detailed description of the invention
The invention discloses a kind of Novel chicken vaccine immunostimulant, this immunostimulant is formed by proper ratio compatible combination by chicken genetically engineered cell factor coniplexes, uses as immunological adjuvant and bacterin preparation compatibility chicken immune when.
In above-mentioned chicken vaccine immunostimulant, chicken genetically engineered cell factor coniplexes is restructuring chicken interferon α 30% ~ 80%, recombination chicken interferon gamma 10% ~ 40%, recombinant IL-2 10% ~ 40%, described immunostimulant adds in vaccine uses, and addition is the 1 ~ 30% of vaccine.This chicken vaccine immunostimulant can be effectively improved humoral immunoresponse(HI) and the cellullar immunologic response level of chicken vaccine; the humoral immunoresponse(HI) level of chicken vaccine can be improved; relatively it is used alone vaccine including vaccine protection period neutralizing antibody level and can improve 2 ~ 4 times; neutralizing antibody generation window phase is relatively used alone vaccine and can shorten 30 ~ 50%; humoral immunoresponse(HI) mark IL-4 secretory volume is relatively used alone vaccine and can improve 1 ~ 3 times; and also the cellullar immunologic response level of chicken vaccine, cellullar immunologic response mark CD3 can be improved+Number and CD4+/CD8+T percentage of lymphocyte is relatively used alone vaccine and improves.
Come further below in conjunction with specific embodiment that the present invention will be described.
1. the development of Novel chicken vaccine immunostimulant
1.1 recombination chicken interferon-ALPHA, recombination chicken interferon gamma, the preparation of recombinant IL-2
First recombination chicken interferon-ALPHA, recombination chicken interferon gamma and the production of recombinant IL-2 are carried out: build containing sequence 1 recombination chicken interferon-ALPHA genes of interest, sequence 2 recombination chicken interferon gamma genes of interest and the engineering colon bacillus of sequence 3 recombinant IL-2 genes of interest as described in sequence table, then engineering bacterium fermentation is carried out, harvest time gathers in the crops bacterium solution, broken, centrifugal bacterium solution takes the supernatant containing destination protein, carry out protein purification, carry out middle product examine and test, or certain density destination protein solution.
The preparation of 1.2 recombinant cytokine complex
The concentration of certified above-mentioned protein solution is adjusted, prepare the recombination chicken interferon-ALPHA solution of 1mg/ml, the recombination chicken interferon gamma solution of 1mg/ml and the recombinant IL-2 solution of 1mg/ml respectively, ratio as required is mixed in proportion, and after mixing, recombination chicken interferon-ALPHA accounts for 30% ~ 80%, recombination chicken interferon gamma accounts for 10% ~ 40%, recombinant IL-2 accounts for 10% ~ 40%.In a preferred embodiment, mixed proportion is restructuring chicken interferon α solution: recombination chicken interferon gamma solution: recombinant IL-2 solution=2:1.5:1.
1.3 lyophilizing
For complex obtained as above, carry out lyophilizing to obtain the immunostimulant agent formulation of lyophilizing.In complex solution obtained as above, add final concentration containing 5% defatted milk powder, 5%GS(glucose) and 10% serum albumin as freeze drying protectant (concentrations above is weight/volume mg/100ml), after mixing, be placed in freeze dryer lyophilizing.The preparation of lyophilizing reduction volume carries out fill, every 2ml, includes the recombination chicken interferon-ALPHA of 2mg, 2mg recombination chicken interferon gamma, 2mg recombinant IL-2.
2, chicken vaccine immunostimulant improves newcastle disease virus inactivated vaccine immune effect
2.1 laboratory animal packets
By 30 20 age in days health broiler chicken, it is randomly divided into 3 groups, often group 10: (1) Novel chicken vaccine immunostimulant+ND Vaccine group；(2) independent ND Vaccine matched group；(3) normal chicken matched group.
2.2 sample collecting
After immunity 1 ~ 6 week, every wing venous blood collection 1ml weekly, 3000r/min are centrifugal went neutralizing antibody level and cytokine IL-4 secretion level in supernatant separation Virus monitory serum, separating peripheral blood mononuclear cells detection t lymphocyte subset group.
2.3 result
2.3.1 neutralizing antibody horizontal detection result
Novel chicken vaccine immunostimulant+ND Vaccine group more independent ND Vaccine group neutralizing antibody level produces and at least shifts to an earlier date 7d, and window phase shortens 50%.It is independent ND Vaccine group 3.5 times that Novel chicken vaccine immunostimulant+ND Vaccine group reaches plateau neutralizing antibody level, and plateau hold time more independent ND Vaccine group leader, Novel chicken vaccine immunostimulant+ND Vaccine group does not occurs reducing to 35d neutralizing antibody level, and individually ND Vaccine group starts to reduce (Fig. 1) to neutralizing antibody level being can be observed after 28d.
2.3.2 IL-4 secretion level testing result
Use IL-4 level in ELISA kit (purchased from Biorbyt company) detection serum.Novel chicken vaccine immunostimulant+ND Vaccine group chicken IL-4 secretion level the 7th day, the 10th day time reach the twice of independent ND Vaccine group, the 14th, 21 days IL-4 secretion levels of Novel chicken vaccine immunostimulant+ND Vaccine group are also higher than independent vaccine group (Fig. 2).
2.3.3 t lymphocyte subset group's testing result
After vaccination, 28d blood sampling carries out FCM analysis (test kit is purchased from Lifespan company).The CD4 of chicken vaccine immunostimulant+ND Vaccine group of the present invention+T lymphocyte content and CD4+/CD8+It is above independent ND Vaccine group, points out chicken vaccine immunostimulant of the present invention+ND Vaccine group cellular immune level more independent ND Vaccine group strong (table 1).
Table 1 Novel chicken vaccine immunostimulant improves ND Vaccine immunity chicken peripheral blood CD3+、CD4+And CD8+T lymphocyte subset group's testing result.
| Group | CD3+ | CD4+/CD8+ |
| Novel chicken vaccine immunostimulant + ND Vaccine group | 68.04% | 1.54 |
| Individually ND Vaccine group | 59.02% | 1.07 |
| Normal chicken matched group | 57.07% | 1.09 |
Above in conjunction with specific embodiments and the drawings, embodiments of the present invention are described in detail, but the invention is not restricted to above-mentioned embodiment, in the ken that art those of ordinary skill is possessed, it is also possible to make a variety of changes on the premise of without departing from present inventive concept.
Sequence table illustrates:
Sequence 1: recombination chicken interferon-ALPHA；Sequence 2: recombination chicken interferon gamma；Sequence 3: recombinant IL-2.
Sequence table
<110>
Anhui Jiuchuan Biotechnology Co., Ltd.
<120>
A kind of chicken vaccine immunostimulant
<130>
2016
<160>
3
<170>
PatentIn version 3.3
<210>
1
<211>
531
<212>
DNA
<213>
Artificial sequence
<400>
1
gcctgcaacc accttcgccc ccaggatgcc accttctctc
acgacagcct ccagctcctc 60
cgggacatgg ctcccacact accccagctg tgcccacagc
acaacgcgtc ttgctccttc 120
aacgacacca tcctggacac cagcaacacc cggcaagccg
acaaaaccac ccacgacatc 180
cttcagcacc tcttcacaat cctcagcagc cccagcactc cagcccactg
gaacgacagc 240
caacgccaaa gcctcctcaa ccggatccac cgctacaccc
agcacctcga gcaatgcttg 300
gacagcagcg acacgcgctc ccggacgcga tggcctcgca
accttcacct caccatcaaa 360
aaacacttca gctgcctcca caccttcctc caagacaacg
attacagcgc ctgcgcctgg 420
gaacacgtcc gcctgcaagc tcgtgcctgg ttcctgcaca
tccacaacct cacaggcaac 480
acgcgcacta agcttgcggc cgcactcgag caccaccacc
accaccactg a 531
<210>
2
<211>
495
<212>
DNA
<213>
Artificial sequence
<400>
2
atgacttgcc agacttacaa cttgtttgtt ctgtctgtca
tcatgattta ttatggacat 60
actgcaagta gtctaaatct tgttcaactt caagatgata
tagacaaact gaaagctgac 120
tttaactcaa gtcattcaga tgtagctgac ggtggaccta
ttattgtaga gaaactgaag 180
aactggacag agagaaatga gaaaaggatc atactgagcc
agattgtttc gatgtacttg 240
gaaatgcttg aaaacactga caagtcaaag ccgcacatca
aacacatatc tgaggagctc 300
tatactctga aaaacaacct tcctgatggc gtgaagaagg
tgaaagatat catggacctg 360
gccaagctcc cgatgaacga cttgagaatc cagcgcaaag
ccgcgaatga actcttcagc 420
atcttacaga agctggtgga tcctccgagt ttcaaaagga
aaaggagcca gtctcagagg 480
agatgcaatt gctaa
495
<210>
3
<211>
432
<212>
DNA
<213>
Artificial sequence
<400>
3
atgatgtgca aagtactgat ctttggctgt atttcggtag
caatgctaat gactacagct 60
tatggagcat ctctatcatc agcaaaaagg aaacctcttc
aaacattaat aaaggattta 120
gaaatattgg aaaatatcaa gaacaagatt catctcgagc
tctacacccc aactgagacc 180
caggagtgca cccagcaaac tctgcagtgt tacctgggag
aagtggttac tctgaagaaa 240
gaaactgaag atgacactga aattaaagaa gaatttgtaa
ctgctattca aaatatcgaa 300
aagaacctca agagtcttac gggtctaaat cacaccggaa
gtgaatgcaa gatctgtgga 360
gctaacaaca agaaaaaatt tcctgatttt ctccatgaac
tgaccaactt tgtgagatat 420
ctgcaaaaat aa
432
Claims (7)
1. a chicken vaccine immunostimulant, it is characterized in that, described chicken vaccine immunostimulant is formed by proper ratio compatible combination by chicken genetically engineered cell factor coniplexes, described chicken genetically engineered cell factor coniplexes includes recombination chicken interferon-ALPHA, recombination chicken interferon gamma and recombinant IL-2, and this three kinds of chicken genetically engineered cell factors ratio by mass in the composite is restructuring chicken interferon α 30% ~ 80%, recombination chicken interferon gamma 10% ~ 40%, recombinant IL-2 10% ~ 40%.
2. chicken vaccine immunostimulant as claimed in claim 1, it is characterized in that, described chicken vaccine immunostimulant consumption in bacterin preparation, based on the described cytokine complex weight with vaccine, cytokine complex weight is the 1 ~ 30% of vaccine weight.
3. chicken vaccine immunostimulant as claimed in claim 1 or 2, it is characterised in that the recombination chicken interferon-ALPHA in described chicken vaccine immunostimulant is as described in the sequence 1 in sequence table.
4. chicken vaccine immunostimulant as claimed in claim 1 or 2, it is characterised in that the recombination chicken interferon gamma in described chicken vaccine immunostimulant is as described in the sequence 2 in sequence table.
5. chicken vaccine immunostimulant as claimed in claim 1 or 2, it is characterised in that the recombinant IL-2 in described chicken vaccine immunostimulant is as described in the sequence 3 in sequence table.
6. chicken vaccine immunostimulant as claimed in claim 1, it is characterised in that described chicken vaccine immunostimulant is to be prepared as water soluble preparation.
7. chicken vaccine immunostimulant as claimed in claim 6; it is characterized in that; the preparation of described chicken vaccine immunostimulant is the lyophilized preparation that can restore with water; in described lyophilized preparation in addition to three kinds of recombinant cytokines; also comprising appropriate freeze drying protectant, described freeze drying protectant comprises defatted milk powder, glucose and serum albumin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610293284.7A CN105944096A (en) | 2016-05-06 | 2016-05-06 | Immunoenhancer for chicken vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610293284.7A CN105944096A (en) | 2016-05-06 | 2016-05-06 | Immunoenhancer for chicken vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105944096A true CN105944096A (en) | 2016-09-21 |
Family
ID=56914313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610293284.7A Pending CN105944096A (en) | 2016-05-06 | 2016-05-06 | Immunoenhancer for chicken vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105944096A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107469076A (en) * | 2017-08-03 | 2017-12-15 | 中国水产科学研究院黑龙江水产研究所 | Application of the albumen of IL 2 in animal vaccine adjuvant is prepared |
| CN108840943A (en) * | 2017-08-09 | 2018-11-20 | 安徽九川生物科技有限公司 | A kind of recombination chicken long-acting interferon γ and the fusion protein and preparation method thereof for preparing this long-acting interferon γ |
| CN109053897A (en) * | 2017-08-09 | 2018-12-21 | 安徽九川生物科技有限公司 | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102404A1 (en) * | 2001-06-18 | 2002-12-27 | Institut National De La Recherche Agronomique | Uses of cytokines |
| CN1408436A (en) * | 2001-09-30 | 2003-04-09 | 扬州大学 | Recombinant Borrel virus combined vaccine |
| CN101365484A (en) * | 2005-08-15 | 2009-02-11 | 瓦克辛公司 | Immunization of avians by administration of non-replicating vectored vaccines |
| CN103495182A (en) * | 2013-09-29 | 2014-01-08 | 河南亚卫动物药业有限公司 | Newcastle disease diad vaccine and preparation method thereof |
| CN104450731A (en) * | 2014-12-11 | 2015-03-25 | 青岛易邦生物工程有限公司 | Production method of chicken gamma interferon protein |
| CN105039474A (en) * | 2015-08-25 | 2015-11-11 | 安徽九川生物科技有限公司 | Preparation method of recombinant chicken interferon-alpha standard substance |
-
2016
- 2016-05-06 CN CN201610293284.7A patent/CN105944096A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102404A1 (en) * | 2001-06-18 | 2002-12-27 | Institut National De La Recherche Agronomique | Uses of cytokines |
| CN1408436A (en) * | 2001-09-30 | 2003-04-09 | 扬州大学 | Recombinant Borrel virus combined vaccine |
| CN101365484A (en) * | 2005-08-15 | 2009-02-11 | 瓦克辛公司 | Immunization of avians by administration of non-replicating vectored vaccines |
| CN103495182A (en) * | 2013-09-29 | 2014-01-08 | 河南亚卫动物药业有限公司 | Newcastle disease diad vaccine and preparation method thereof |
| CN104450731A (en) * | 2014-12-11 | 2015-03-25 | 青岛易邦生物工程有限公司 | Production method of chicken gamma interferon protein |
| CN105039474A (en) * | 2015-08-25 | 2015-11-11 | 安徽九川生物科技有限公司 | Preparation method of recombinant chicken interferon-alpha standard substance |
Non-Patent Citations (7)
| Title |
|---|
| KALIPADA PAHAN等: ""N-ACETYL CYSTEINE INHIBITS INDUCTION OF NO PRODUCTION BY ENDOTOXIN OR CYTOKINE STIMULATED RAT PERITONEAL MACROPHAGES, C6 GLIAL CELLS AND ASTROCYTES"，第39-48页", 《FREE RADICAL BIOLOGY & MEDICINE》 * |
| SAXENA,M.: "AJ578467.1，"Gallus gallus mRNA for Interleukin-2"", 《GENBANK DATABASE》 * |
| 于涟等: "鸡白细胞介素2对H5亚型禽流感疫苗免疫增强作用研究", 《中国畜牧兽医学会禽病学分会第十二次学术研讨会论文集》 * |
| 刘建: "干扰素作为免疫调节剂在商品肉鸡上的应用研究", 《山东农业大学全日制硕士专业学位论文》 * |
| 曾岩等: "重组鸡Y-干扰素对H5亚型禽流感灭活苗的免疫增强作用", 《东北农业大学学报》 * |
| 贾立军等: "鸡γ干扰素对H5亚型禽流感疫苗的免疫增强作用", 《农业生物技术学报》 * |
| 邵卫星: ""分别表达鸡白细胞介素1β、白细胞介素2和骨髓单核细胞生长因子基因重组鸡痘病毒的构建及其对ND疫苗免疫效力的影响"，D050-63", 《中国博士学位论文全文数据库 农业科技辑》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107469076A (en) * | 2017-08-03 | 2017-12-15 | 中国水产科学研究院黑龙江水产研究所 | Application of the albumen of IL 2 in animal vaccine adjuvant is prepared |
| CN107469076B (en) * | 2017-08-03 | 2020-07-07 | 中国水产科学研究院黑龙江水产研究所 | Application of IL-2 protein in preparation of animal vaccine adjuvant |
| CN108840943A (en) * | 2017-08-09 | 2018-11-20 | 安徽九川生物科技有限公司 | A kind of recombination chicken long-acting interferon γ and the fusion protein and preparation method thereof for preparing this long-acting interferon γ |
| CN109053897A (en) * | 2017-08-09 | 2018-12-21 | 安徽九川生物科技有限公司 | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101035558B (en) | Multivalent canine vaccines against leptospira bratislava and other pathogens | |
| Chandran et al. | Immunisation of Indian major carps against Aeromonas hydrophila by intraperitoneal injection | |
| CN105944096A (en) | Immunoenhancer for chicken vaccine | |
| CN102221618B (en) | Method for establishing hog cholera lapinized virus labeled vaccine strain and preparing vaccine | |
| CN106267182A (en) | The preparation method of a kind of porcine pseudorabies virus subunit vaccine and vaccine combination and application | |
| CN108117583B (en) | Immunopotentiator and application thereof | |
| CN103275228A (en) | K99-987P-F41 recombinant protein and application thereof | |
| CN103614387B (en) | The carrying Cap gene of porcine circovirus type 2 gene optimized and recombinant plasmid and application | |
| CN104894045A (en) | Recombinant lactobacillus for coexpression of foot and mouth disease virus VP1 gene and immunoadjuvant cattle IL-6 gene, and preparation method and application of recombinant lactobacillus | |
| CN101638661B (en) | Construction of recombinant lactic acid bacteria with HN gene and F gene of Newcastle disease virus | |
| CN106310250A (en) | Swine fever oral attenuated freezing-dry vaccine and preparation method thereof and freeze-drying protective agent | |
| CN106177945A (en) | A kind of pig vaccine immunostimulant, its preparation method and application | |
| CN102038948A (en) | Vaccine for controlling persistent infection of hepatitis B virus | |
| Capone et al. | GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial | |
| CN101934073B (en) | Bovine viral diarrhea virus (BVDV) transgenosis astragalus mongholicus vaccine and production method | |
| CN102311928B (en) | Recombinant yeast engineering strain coexpressed by proteins of chicken anaemia viruses VP1 and VP2, construction method thereof and application thereof | |
| CN101155596B (en) | Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis | |
| CN111944017B (en) | Polypeptide for promoting pig body to generate broad-spectrum acquired immune response and application thereof | |
| CN107007831A (en) | The immunologic adjuvant of hepatitis B DNA vaccine | |
| Franz et al. | Immunomodulatory effect of Bacillus toyonensis BCT-7112 supplementation in puppies vaccinated against canine parvovirus | |
| CN104548081A (en) | Fusion protein CTT3H contained tuberculosis subunit vaccine and vaccine adjuvants | |
| CN105524149A (en) | Mycobacterium tuberculosis protein HBHA (heparin-binding hemagglutinin adhesion) and expression method and subunit vaccine thereof | |
| CN104587463A (en) | Activating effect of fish NKEF-A (Natural Killer Enhancer Factor-A) recombinant protein on adaptive humoral immunity and application of recombinant protein | |
| CN101892189B (en) | Transformant for blocking effect of porcine somatostatin by oral immunization and application thereof | |
| CN107432929B (en) | Animal composite immunopotentiator and application thereof, and method for determining optimal component content of immunopotentiator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Yu Inventor after: Ma Tengfei Inventor after: Wang Lili Inventor after: Cha Yingli Inventor after: Fu Xiule Inventor after: Zhou Wei Inventor after: Qi Shimei Inventor after: Li Shuqi Inventor after: Gao Yaohui Inventor after: Lai Pengfei Inventor after: Wang Liangqing Inventor before: Wang Mingli Inventor before: Lai Pengfei Inventor before: Wang Liangqing Inventor before: Ma Tengfei Inventor before: Wang Lili Inventor before: Gan Lin Inventor before: Zhao Jun Inventor before: Zhao Yu Inventor before: Cha Yingli Inventor before: Fu Xiule Inventor before: Zhou Wei Inventor before: Qi Shimei Inventor before: Li Shuqi Inventor before: Gao Yaohui |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |
|
| RJ01 | Rejection of invention patent application after publication |